Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Obesity
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Hyperlipidemia
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) - MK-0616-037 - Merck Sharp & Dohme LLCSee more